Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


SAGE Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

August 3, 2017
Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update

July 20, 2017
Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017

July 10, 2017
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read More News

Associated Team Members

Kevin Starr
Partner